Literature DB >> 18853585

Glomerular hyperfiltration and albuminuria in critically ill patients.

O Fuster-Lluch1, M Gerónimo-Pardo, R Peyró-García, M Lizán-García.   

Abstract

Glomerular hyperfiltration and albuminuria are two pathological conditions that could alter renal drug elimination, but they have been rarely studied in a critical care setting. The aims of this descriptive, prospective study performed on 89 critically ill patients are to determine rates of glomerular hyperfiltration (main objective) and albuminuria (secondary objective). On admission, 17.9% of patients presented with glomerular hyperfiltration, climbing to rates as high as 30% during the first week of admission. Seventy-five percent showed albuminuria on admission, with rates remaining high throughout the week of the study. Since glomerular hyperfiltration as well as albuminuria are frequent pathophysiological conditions in critical care patients, the implications that these phenomena may have regarding drug elimination need further evaluation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18853585     DOI: 10.1177/0310057X0803600507

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  37 in total

Review 1.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

2.  Sepsis-related hypertensive response: friend or foe?

Authors:  Mohamed Saleh
Journal:  BMJ Case Rep       Date:  2014-05-22

Review 3.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

4.  Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach.

Authors:  Federico Pea; Pierluigi Viale; Piergiorgio Cojutti; Mario Furlanut
Journal:  Antimicrob Agents Chemother       Date:  2012-10-08       Impact factor: 5.191

5.  Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.

Authors:  Mohd H Abdul-Aziz; Azrin N Abd Rahman; Mohd-Basri Mat-Nor; Helmi Sulaiman; Steven C Wallis; Jeffrey Lipman; Jason A Roberts; Christine E Staatz
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

6.  Sepsis-associated renal salt wasting: how much is too much?

Authors:  Mohamed Saleh
Journal:  BMJ Case Rep       Date:  2014-01-09

7.  Accuracy of the estimation of glomerular filtration rate within a population of critically ill patients.

Authors:  João Pedro Baptista; Marta Neves; Luis Rodrigues; Luísa Teixeira; João Pinho; Jorge Pimentel
Journal:  J Nephrol       Date:  2014-01-21       Impact factor: 3.902

8.  Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients.

Authors:  Clément Boidin; Laurent Bourguignon; Sabine Cohen; Claire Roger; Jean-Yves Lefrant; Jason A Roberts; Bernard Allaouchiche; Alain Lepape; Arnaud Friggeri; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 9.  [Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?]

Authors:  A Brinkmann; A C Röhr; A Köberer; T Fuchs; J Preisenberger; W A Krüger; O R Frey
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-09-13       Impact factor: 0.840

Review 10.  Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?

Authors:  Federico Pea; Pierluigi Viale
Journal:  Crit Care       Date:  2009-06-10       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.